Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.
Related to this article
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and pCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Advertisement
Advertisement
Trending on Urology Times
1
Decipher may help identify ADT benefit in intermediate-risk prostate cancer
2
Evaluating AI Tools for Prostate Cancer: What Urologists Should Ask
3
Using AI Risk Estimates in Prostate Cancer Treatment Decisions
4
How can urologists separate personalized medicine from marketing?
5